Which of the following drugs is a LAMA used to manage COPD?

Umeclidinium is a long-acting muscarinic antagonist (LAMA) specifically used in the management of chronic obstructive pulmonary disease (COPD). LAMAs work by blocking the action of acetylcholine on muscarinic receptors in the airways, leading to bronchodilation and improved airflow. This mechanism is particularly beneficial for patients with COPD, as it helps alleviate symptoms such as dyspnea and enhances overall lung function.

In the context of COPD management, LAMAs like umeclidinium are often preferred for their long duration of action, allowing for once-daily dosing. This enhances patient compliance and provides sustained control of symptoms.

Other options listed serve different purposes: Albuterol is a short-acting β2-adrenergic agonist used primarily for quick relief of bronchospasm, while Fluticasone and Beclomethasone are corticosteroids that reduce inflammation in the airways but are not categorized as bronchodilators. Therefore, Umeclidinium stands out as the appropriate choice for managing COPD through its specific action as a LAMA.